Prescription drug use in pregnancy
Prescription drug use in pregnancy
复制标题
DOI：
10.1016/j.ajog.2004.04.025
复制
发表时间：
2004-08-01
影响因子：
9.8
通讯作者：
Platt, Richard
中科院分区：
文献类型：
--
作者：
Andrade, Susan E.;Gurwitz, Jerry H.;Platt, Richard
目的：本研究的目的是提供有关使用处方药的孕妇在UnitedStates.Study设计的患病率的信息：一项回顾性研究进行了使用的自动化数据库的8个健康维护组织，参与了健康维护研究网络中心的教育和治疗研究。确定了1996年1月1日至2000年12月31日期间在医院分娩婴儿的妇女。根据治疗类别和美国食品药品监督管理局风险分类系统评估处方药使用情况，假设妊娠期为270天，妊娠期为3个90天，妊娠前为90天。非处方药的使用没有assessed.Results：在1996年至2000年期间，152,531交付确定符合标准的研究。在98，182例分娩（64%）中，在分娩前270天内处方了维生素或矿物质补充剂以外的药物：3，595名妇女（2.4%）接受A类药物; 76，292名妇女（50.0%）接受B类药物; 57 604名妇女（37.8%）接受C类药物; 7333名女性（4.8%）接受了D类药物，6976名女性（4.6%）接受了美国食品和药物管理局风险分类系统X类药物。总共有5157名妇女（3.4%）接受了D类药物，1653名妇女（1.1%）在首次产前检查后接受了X类药物。我们发现，几乎一半的孕妇接受了C、D类处方药，美国食品和药物管理局风险分类系统的X或X强调了需要了解这些影响的重要性药物对发育中的胎儿和孕妇的影响。(C)2004爱思唯尔公司All rights reserved.
Objective: The purpose of this study was to provide information on the prevalence of the use of prescription drugs among pregnant women in the United States.Study design: A retrospective study was conducted with the use of the automated databases of 8 health maintenance organizations that are involved in the Health Maintenance Research Network Center for Education and Research on Therapeutics. Women who delivered of an infant in a hospital from January 1, 1996, through December 31, 2000, were identified. Prescription drug use according to therapeutic class and the United States Food and Drug Administration risk classification system was evaluated, with the assumption of a gestational duration of 270 days, with three 90-day trimesters of pregnancy, and with a 90-day period before pregnancy. Nonprescription drug use was not assessed.Results: During the period 1996 through 2000, 152,531 deliveries were identified that met the criteria for study. For 98,182 deliveries (64%), a drug other than a vitamin or mineral supplement was prescribed in the 270 days before delivery: 3595 women (2.4%) received a drug from category A; 76,292 women (50.0%) received a drug from category B; 57,604 women (37.8%) received a drug from category C; 7333 women (4.8%) received a drug from category D, and 6976 women (4.6%) received a drug from category X of the United States Food and Drug Administration risk classification system. Overall, 5157 women (3.4%) received a category D drug, and 1653 women 1.1%) received a category X drug after the initial prenatal care visit.Conclusion: Our finding that almost one half of all pregnant women received prescription drugs from categories C, D, or X of the United States Food and Drug Administration risk classification system highlights the importance of the need to understand the effects of these medications on the developing fetus and on the pregnant woman. (C) 2004 Elsevier Inc. All rights reserved.